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Background: During the pandemic outbreak of the 2009 swine influenza (A(H1N1)
pdm09), 32 fatal cases occurred in Norway and 19 of these were included in this study.
Objectives: We characterised pulmonary changes in these fatal Norwegian cases.
Patients and Methods: Upon hospitalisation, detailed clinical information and specimens 
from the upper and lower respiratory pathways were collected. At post- mortem, lung tis-
sue was collected, formalin- fixed and paraffin- embedded. Immunohistochemical and light 
microscopic examination was performed to visualise the local expression of the A(H1N1)
pdm09 virus. Reverse transcription- polymerase chain reaction (RT- PCR) and pyrose-
quencing of the non- fixed specimens allowed the identification of mutations in the influ-
enza virus surface glycoprotein (haemagglutinin gene) particularly at position 222.
Results and Conclusions: The overall course of illness lasted from 2 to 40 days (median 
9 days). Diffused alveolar damage (DAD) was evident in 11 cases, 4 of which had no 
apparent underlying illness. Obesity was prominent in 12 cases, where three individu-
als were classified as otherwise healthy. The HA D222G mutation was detected in six 
cases, 3 of which had no underlying illness. Immunohistochemistry showed the 
A(H1N1)pdm09 virus to be prominent at the site of inflammation both in close prox-
imity to and inside alveolar structures in the lung tissue. In addition to a possible role 
for the HA D222G mutation, our findings indicate that host factors and underlying 
conditions in the infected individuals are fundamental for disease outcome in many 
cases. This study increases our understanding of determinants for the clinical outcome 
of pandemic influenza, which could guide future treatment.
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1  | INTRODUCTION
In April 2009, an outbreak of a novel influenza A virus of swine ori-
gin was discovered in Veracruz, Mexico, subsequently referred to as 
influenza A(H1N1)pdm09.1,2 In the following months, the virus rapidly 
spread worldwide causing the World Health Organization (WHO), on 
11 June 2009, to declare the first influenza pandemic of the 21st cen-
tury. During the first wave of the 2009 pandemic, Norway, with a pop-
ulation of 4.9 million people,3 was comparably well prepared for the 
ongoing pandemic.4–10 Norway had access to a pandemic vaccine and 
aBoth authors contributed equally
bSee Appendix 1 for authors in Norwegian lung pathology group.
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mass vaccination started 1–3 weeks prior to the peak of the pandem-
ic, resulting in high vaccination coverage (45%) and reduced morbidity 
and mortality.11 Emergency plans were in place, but fortunately the 
high number of hospitalisations which were planned for in the reason-
able worst case scenario did not occur. In total, 1300 people diagnosed 
with influenza were hospitalised, 200 patients received intensive care, 
and 32 patients died with laboratory- verified infection.12,13 Despite 
being described as a relatively mild pandemic, some young healthy 
individuals experienced severe illness and occasional mortality.14–18 
Interestingly, elderly patients (>65 years old) were much less severely 
affected, probably due to pre- existing cross- reactive immunity gener-
ated by infection with similar H1N1 viruses in early life.19
Post- pandemic studies have described the clinical aspects of the 
A(H1N1)pdm2009, where several host factors and underlying con-
ditions, such as pneumonia, obesity and pregnancy, have been asso-
ciated with disease severity.9,14–16,20–22 Also, the impact of vaccines 
and neuraminidase inhibitors used during the pandemic has been 
investigated.23–25 Interestingly, viral factors, such as mutations alter-
ing the receptor- binding specificity of the virus, have been identified 
and associated with severe disease outcome.26–30 Moreover, the most 
severe clinical cases from the A(H1N1)pdm09 have been shown to 
relate to the severity of lung pathological damage, as observed pre-
viously in the highly virulent 1918 pandemic and in zoonotic avian 
H5N1 cases. In addition to inflammation of the larger airways, these 
viral infections involve the alveolar walls and may cause diffused alve-
olar damage (DAD) in susceptible individuals.
In the current study, we performed a clinicopathological analysis 
of 19 fatal, autopsied Norwegian cases from the 2009 pandemic. We 
amplified the influenza virus haemagglutinin (HA) gene to identify 
possible genetic viral mutations and visualised the expression of the 
A(H1N1)pdm09 virus inflammation in the lung tissue of autopsied 
subjects. Our results show a possible association between obesity, 
pre- existing illness, the viral mutation HA D222G and mortality in fatal 
Norwegian cases.
2  | MATERIALS AND METHODS
2.1 | Study population
Nineteen hospitalised fatal autopsied cases with laboratory- verified 
A(H1N1)pdm09 infection (13 males and 6 females, aged 9–69 years 
old) were included in our study. Patients were admitted to clinical 
wards at Oslo University Hospital, Akershus county, Lillehammer, 
Kristiansand, Haukeland University Hospital in Bergen and St. Olav 
Hospital in Trondheim. Two cases were sudden, unexpected deaths 
that occurred outside hospital, and according to regulation reported 
to the police who ordered forensic autopsy. Clinical and demographic 
information (Table 1) and also respiratory tract and lung swabs were 
collected upon hospitalisation. In addition, lung/bronchial tissue was 
collected post- mortem and examined by an experienced pulmonary 
pathologist. The Regional Ethics Committee of Western Norway 
approved this study and the use of samples without patient consent 
(REC2009/1224).
2.2 | Sequence analysis
Viral RNA was extracted using a total nucleic acid extraction kit in the 
MagNA Pure LC System (Roche Diagnostics, Mannheim, Germany). In 
general, a modification of the full genome sequencing protocol pro-
vided by CDC, USA,31 was used for virus isolates, whereas sequencing 
of the amplicon from a more sensitive RT- PCR32 was used for many of 
the primary specimens.
A pyrosequencing assay was used to detect D222G muta-
tions in the HA1 gene in the Norwegian A(H1N1)pdm09 cases as 
described previously.30 Briefly, a 110- nucleotide amplicon encom-
passing the HA 222 amino acid region was generated from 5 μL 
specimen RNA combined with each of primers pyro- H1 forward: 
5′- AGTTCAAGCCGGAAATAGCA- 3′ and pyro- H1 reverse: 5′- biotin- 
TTTCCAGTTGCTTCGAATGTT- 3′ and reagents from the SuperScript 
III One- Step RT- PCR System with Platinum Taq High Fidelity kit 
(ThermoFisher Scientific, Waltham, MA, USA) in a 25 μL reaction and 
subjected to the following cycling conditions: 30 minutes at 50°C, 
2 minutes at 94°C; 45 cycles of 15 seconds denaturation at 94°C, 
30 seconds annealing at 55°C and 1 minute extension at 68°C; finally, 
5 minutes at 68°C for final extension.
The pyrosequencing reactions were performed as previ-
ously described33 using a residue- specific sequencing primer 
(5′- AGCAATAAGACCCAAAGTGAGG- 3′). The sequenced region 
begins at nucleotide 747 in the full- length sequence of the viral RNA 
segment 4, where nucleotides 747–749 encode HA1 amino acid 222. 
The most common wild- type codon in this position is GAT, which 
encodes aspartic acid (D). The GAA codon encodes glutamic acid (E), 
while GGT (or GGA) gives glycine (G). Mutation of G to A in the first 
position of the GAT codon gives asparagine (N).
2.3 | Immunohistochemistry
Routine haematoxylin–eosin- stained sections of formalin- fixed, 
paraffin- embedded lung tissue were prepared according to the stand-
ard protocols.
Immunohistochemical staining was performed by the EnVision 
technique (K5007, Dako, Glostrup, Denmark) following the man-
ufacturer’s instructions, and 1:1000 dilution of anti- influenza A 
matrix protein (E10) antibody (#EMS009, KeraFAST, Boston, MA, 
USA).34,35
2.4 | Light microscopy and evaluation of 
immunohistochemical staining
All sections were studied using a light microscope (Leica DMLB, Leica 
Microsystems Wetzlar, Germany) by three investigators. Sections 
were scored blindly by two investigators to assess the degree of 
A(H1N1)pdm09 staining in the lung tissue. Depending on the degree 
of positivity, the number 0, 1 or 2 was assigned for each category 
during assessment, where 0 was considered negative, 1 was regard-
ed positive and 2 represented strongly positive. As two sections 
were evaluated from each subject, the mean score value from both 
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sections was calculated for each individual. Cells were considered 
positive when ≥50% of the cell membrane was positively stained by 
antibody.
2.5 | Statistical significance
Statistical significance was evaluated by the Student t test and pre-
sented as the mean. Differences were considered significant when 
P≤.05. In addition, the Pearson correlation test was used to examine 
the association between the different parameters.
3  | RESULTS
3.1 | Obesity and pre- existing illness as contributors 
to disease severity in the 2009 pandemic influenza A 
H1N1 fatal Norwegian cases
The nineteen fatal cases that were hospitalised during the 2009 pan-
demic in Norway consisted of 13 males and 6 females, aged 9–69 years 
old. Generally, the course of disease lasted 2–40 days. In 15 individuals 
(79%), the course of infection was ≤14 days. Moreover, neuraminidase 
TABLE  1 Patients’ demographics
Patient Gender Age (y)
Weight 
(kg) BMI Obesity Pre- existing disease
Duration of 




1 M 50–59 110 32 + Healthy 7 Virus pneumonia. 
HM
−
2 F 40–49 128 48 + Asthma 7 Bacterial pneumonia +
3 F 11–20 – – − Congenital 
cardiomyopathy
9 Virus pneumonia +
4 M 20–29 121 35 + Healthy 40 Virus pneumonia. 
HM. DAD
+
5 F 1–10 – – − Eisenmenger 
syndrome/Trisomia
8 Virus pneumonia. 
HM. DAD
−
6 M 11–19 37 17 − Autoimmune disease/
cancer
2 Bacterial pneumonia −
7 F 30–39 148 53 + Healthy 11 Virus pneumonia. 
HM. DAD
−
8 M 20–29 115 37 + Healthy 10 Virus pneumonia. 
HM. DAD
−
9 F 60–69 73 31 + Asthma/Rheumatoid 
Arthritis




10 M 50–59 108 35 + Arteriosclerosis 35 Virus pneumonia. 
HM. DAD
+
11 F 50–59 114 39 + Myelomatosis 14 Virus pneumonia. 
HM
−




13 M 30–39 58 23 − Healthy 7 Virus pneumonia. 
HM. DAD
+
14 M 40–49 85 25 − Chronic lymphatic 
leukaemia
20 Virus pneumonia. 
DAD. ARDS
−
15 M 50–59 90 31 + Hypertension 10 Virus pneumonia. 
HM. DAD
−
16 M 30–39 98 36 + Pancreatitis/alcoholic 
liver disease
31 Fungus pneumonia 
(Aspergillus)
+
17 M 30–39 79 29 − Healthy 2 Virus pneumonia. 
HM
−
18 M 40–49 97 29 − Hypertension/
Diabetes II
3 Virus pneumonia. 
HM. ARDS
−
19 M 50–59 73 24 − Chronic lymphatic 
leukaemia
7 Virus pneumonia. 
HM. DAD
+
M, male; F, female; BMI, body mass index; HM, hyaline membranes; DAD, diffused alveolar damage; ARDS, acute respiratory distress syndrome.
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inhibitors (laninamivir/oseltamivir (Tamiflu) 75 mg/peramivir/zanamivir 
(Relenza)) were administered to nine patients (47%). Underlying disease 
was observed in 12 of the cases (63%). Three of the 7 previously healthy 
patients (six males and one female) received neuraminidase inhibitors.
Light microscopic examination of the lung tissue revealed that 14 
patients had viral pneumonia, of which 11 showed hyaline membranes. 
In the remaining five patients, two had bacterial infection, one had a 
mixed viral and bacterial infection, one had fungal infection (aspergillus), 
and one had no apparent infection in the tissue (Table 1). Interestingly, 
post- mortem examination of the lung tissue revealed that DAD was 
evident in 11 individuals (78%) (eight males) with 4 of these had DAD, 
but no apparent pre- existing illness. Three patients had acute respi-
ratory distress syndrome pattern (ARDS), 2 of these patients showed 
changes consistent with viral pneumonia and 1 patient most likely had 
a mixed viral and bacterial infection.36 None of the three patients with 
clinical ARDS showed DAD morphologically. Meanwhile, 2 had only 
viral infection and 1 demonstrated a mixed viral and bacterial infection.
Obesity has been shown to be a prominent contributor to disease 
severity during the pandemic. Twelve patients (eight males and four 
females, ages 27–69 years) had body mass index (BMI) ranging from 
29 to 53. The overall course of illness ranged from 2 to 40 days (medi-
an 9 days), while in the obese cases the range was 7–40 days, with a 
slightly longer median of 12 days. Interestingly, 5 of 7 individuals with 
no known pre- existing illness were obese. In addition to this, 6 of the 
obese cases had DAD in their lung tissue (Table 1).
3.2 | A Haemagglutinin viral mutation (HA 
D222G) in A(H1N1)pdm09 is associated with severe 
disease outcome
Swabs from the upper and lower respiratory tract were collected from 
15 of the fatal cases allowing genetic analysis of the viral haemagglutinin 
gene, using conventional (Sanger) sequencing or pyrosequencing. The 
viral genotype at amino acid position 222 of the haemagglutinin (HA) 
gene was determined in 15 individuals. The HA substitution D222G was 
detected in six cases (four males and two females, aged 25–59 years), 
while the other nine patients possessed the wild- type D222D. 
Interestingly, disease duration was ≤14 days in 5 of the subjects pos-
sessing the HA mutation, while obesity was prominent in 4 of the cases. 
No apparent association between swab location and detection of the 
HA D222G mutation was observed in these subjects (Table 2).
3.3 | Detection of influenza- specific cells in the 
lung tissue
Immunohistochemical staining was performed on paraffin- embedded 
formalin- fixed lung tissue sections to identify influenza- specific cells. 
This visualisation provided us with a more detailed understanding of the 
viral expression pattern at the site of inflammation, which was promi-
nent, both in close proximity to and inside alveolar structures (Fig. 1A). 
Moreover, the degree of A(H1N1)pdm09 staining in the lung tissue was 
evaluated (Fig. 1B). Two tissue sections were evaluated from each sub-
ject, where the mean score value from both sections was calculated and 
illustrated. Most of the patients showed a staining score of 0<1 (14 sub-
jects) and 1<2 (12 subjects), while only two subjects had a staining score 
of 2. Although no direct association between disease severity and stain-
ing intensity could be observed, the high number of staining score 0 could 
be a result of tissue destruction as a consequence of disease severity.
4  | DISCUSSION
Since the outbreak of the novel A(H1N1)pdm09, post- pandemic studies 
have described the clinical aspects of this virus.23–25 Several host factors 
TABLE  2 Patients’ qPCR values for H1N1
Patient Gender Age (y) Influenza A H1N1 Ct value Mutation Swab location
1 M 50–59 + + 28.9 222G (+) Lung, trachea, upper respiratory tract
2 F 40–49 + + 23.3 222D (−) Lung, trachea, upper respiratory tract
3 F 11–20 + + 30.1 222D (−) Trachea, upper respiratory tract, nasopharyngeal airway
4 M 20–29 + + 35.4 222D (−) Trachea
5 F 1–10 + + 16.3 222D (−) Nasopharyngeal airway
6 M 11–19 + + 25.8 222D (−) Nasopharyngeal airway
7 F 30–39 + + 26.9 222G (+) Lung, nasopharyngeal airway
8 M 20–29 + + 26.3 222G (+) Lung, trachea
9 F 60–69 + + 36.5 222D (−) Nasopharyngeal airway
10 M 50–59 + + 35.4 222D (−) Nasopharyngeal airway
11 F 50–59 + + 27.6 222D (−) Nasopharyngeal airway
12 M 40–49 + + 23.9 222D (−) Lung, nasopharyngeal airway
13 M 30–39 + + 21.6 222G (+) Lung, nasopharyngeal airway
14 M 40–49 + + 24.1 222G (+) Lung
15 M 50–59 + + 32.7 222G (+) Nose, bronchus
M, male; F, Female.
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and underlying conditions have been associated with disease sever-
ity.9,14–16,20–22 These include pneumonia, obesity, pregnancy, in addition 
to effects of vaccines and neuraminidase inhibitors that were used dur-
ing the pandemic.23–25 Kilander et al.29 reported a novel mutation in the 
major surface glycoprotein HA) of A(H1N1)pdm09, namely HA D222G, 
which was associated with a severe clinical outcome in Norwegian 
patients.30 The mutation was found with considerable frequency in fatal 
and severe cases (11 of 61 cases), but was not observed in any of the 205 
mild cases included in their study. Other subsequent studies have found 
this mutation at considerable frequency in fatal and severe cases.26,28–30 
In this study, sequence analysis of the A(H1N1)pdm09 virus showed that 
many of the genetic markers associated with virulence were not present. 
Moreover, the most severe clinical pandemic cases also showed severe 
pathological damage in the lungs, where in susceptible individuals inflam-
mation of the alveolar walls resulted in DAD. Therefore, we further 
investigated whether there was an association between the genetic viral 
HA D222G mutation and the expression of the A(H1N1)pdm09 virus 
locally at the site of inflammation in the lung tissue. In this study, we per-
formed a thorough characterisation of nineteen of the fatal Norwegian 
pandemic cases. The increased morbidity encountered with the virus is 
related to infection of cells in the upper and lower airways and ultimately 
resulting in DAD.37 Here, we identified possible genetic viral mutations, 
while additionally visualising the expression of the A(H1N1)pdm09 virus 
locally in the lung tissue of these subjects.
Our results demonstrated that of the 19 fatal cases that were 
hospitalised during the pandemic in Norway, the course of infection 
was ≤14 days in 79% of these cases. Neuraminidase inhibitors were 
administered to 47%. Compared with no treatment, neuraminidase 
inhibition therapy has previously been associated with a reduction in 
mortality risk regardless of timing.25 Interestingly, evaluation of the 
lung tissue from our fatal cases revealed that 11 individuals had DAD 
(78%) and 4 of these patients were seemingly healthy and without 
apparent pre- existing illness.38 With a short overall course of illness 
that lasted a range of 2–40 days, all 4 previously healthy individuals 
had a surprisingly short course of infection of ≤11 days (Table 1).
As observed previously, obesity was also a prominent contributor 
to disease severity during the pandemic in these 19 fatal cases,39 12 
had a BMI that ranged from 29 to 55, and an overall course of illness 
that lasted a range of 7–40 days. Interestingly, 6 of the obese subjects 
showed DAD in their lung tissue, 3 of which belonged to the healthy 
group of individuals with no apparent pre- existing illness (Table 1). This 
suggests that a high BMI may influence the susceptibility of develop-
ing DAD in healthy individuals.
All subjects in this study were positive by real- time PCR for 
A(H1N1)pdm09 virus. The viral mutation HA D222G was observed in 
6 of 15 cases where the genotype in this position could be ascertained, 
while the other nine patients possessed the wild- type 222D.30,40,41 
Interestingly, all four subjects who developed DAD and had no pre- 
existing illness expressed the HA D222G viral mutation in their lung 
tissue (Table 2). This suggests that, similar to obesity, the expression 
of the HA D222G viral mutation at the site of inflammation predis-
poses to viral pneumonia and development of DAD with an associat-
ed increased mortality rate. Whereas the likelihood of occurrence of 
this and other mutations may increase the duration of infection, the 
duration of illness before death was found to be comparably short for 
these cases of HA D222G in previously healthy individuals. Due to the 
nature of the study, only fatal cases were included and further studies 
comparing the whole viral genome sequence between mild and fatal 
cases may shed light on the role of the virus in mortality.
F IGURE  1 Detection of influenza A H1N1- specific cells locally at 
site of inflammation in the lung tissue of fatal Norwegian cases. (A) 
Immunohistochemical staining was performed on paraffin- embedded 
formalin- fixed lung tissue sections to identify influenza- specific cells 
(brown) at site of inflammation. These were observed sporadically 
throughout the tissue (A, B), and were also detected in close 
proximity to and inside alveolar structures (C, D). Some cases had less 
(E, F) influenza- specific cells at the site of inflammation than others 
(A, B and C, D). (B) The degree of H1N1 staining in the lung tissue 
was evaluated. Depending on the level of staining, either number 0, 
1 or 2 was assigned for each category during assessment, where 0 
was considered negative, 1 was regarded positive and 2 represented 
strongly positive. The x- axis illustrates the degree of staining, while 
the y- axis indicates the number of patients

























530  |     VoltersVik et al.
The identification and visualisation of A(H1N1)pdm09- specific 
cells on paraffin- embedded formalin- fixed lung tissue sections from 
the subjects, using immunohistochemistry, provided us with a more 
detailed understanding of the viral expression pattern at the site of 
inflammation.42 These influenza- specific cells were prominent, both in 
close proximity to and inside alveolar structures in the tissue (Fig. 1A). 
Moreover, evaluating the degree of H1N1 staining in the lung tissue 
and the distribution of the staining intensity revealed that 74% of the 
patients had a relatively low staining score of 0<1 (14 subjects), while 
only two subjects had a staining score of 2 (Fig. 1B). No direct asso-
ciation between disease severity and staining intensity was observed 
in these 19 cases. We could not, however, ignore the possibility that 
both differences in disease severity and post- mortem procedures have 
influenced the quality of the material examined, which may explain the 
rather high number of staining score 0. Virus- induced inflammation 
probably causes lung pathology, but tissue destruction can also be a 
result of immune- mediated killing of virus- infected. Therefore, the role 
of immune cells, particularly cytotoxic T cells, in lung pathology should 
be evaluated in future studies.
In conclusion, our results show a possible association in fatal 
Norwegian cases from the A(H1N1)pdm09 pandemic between mortali-
ty and the factors obesity, underlying illness, and the viral mutation HA 
D222G. Furthermore, the visualisation of influenza- specific cells in lung 
tissue sections from these same individuals provided us with a deeper 
understanding of the viral expression pattern at the site of inflamma-
tion. Combined, our results suggest that in many cases both underlying 
conditions and host factors in the infected individuals were fundamen-
tal for disease outcome, rather than the virus itself. This study expands 
our understanding of determinants for the clinical outcome of pandem-
ic influenza, which could in turn guide future treatment.
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